In this session, our panel will analyse the latest dealmaking data to see what’s working, what’s not, and what both sides of the negotiation table can do to secure productive deals.
Our panel will ask:
- What’s capturing Big Pharma’s attention?
- Which therapy areas and technologies are attracting investment?
- Are assets really being licensed earlier in the development process?
- How can players in Asia strike deals with the US and EU?
- What goes into a successful deal and what data do you need to focus on?
